CAPRICOR THERAPEUTICS, INC. - 8-K Filing
Capricor Therapeutics filed a lawsuit against Nippon Shinyaku Co., Ltd. and its U.S. subsidiary, NS Pharma Inc., over the parties' U.S. distribution agreement for Deramiocel, Capricor's investigational cell therapy for Duchenne muscular dystrophy (DMD). The complaint alleges that NS failed to prepare for the commercial launch of Deramiocel and contains a fundamental pricing flaw preventing patient access through Medicare, Medicaid, or private insurance. Capricor seeks rescission of the agreement and injunctive relief. (Items: 7.01 of this Current Report on Form 8-K, Exhibit 99)
Tickers: $CAPR